Roivant Sciences Ltd [NASDAQ: ROIV] stock went on an upward path that rose over 0.34% on Tuesday, amounting to a one-week price increase of more than 5.32%.
Over the last 12 months, ROIV stock rose by 17.86%. The one-year Roivant Sciences Ltd stock forecast points to a potential upside of 29.87. The average equity rating for ROIV stock is currently 1.18, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for the stock reached $8.79 billion, with 806.68 million shares outstanding and 376.18 million shares in the current float. Compared to the average trading volume of 6.08M shares, ROIV stock reached a trading volume of 3902656 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Roivant Sciences Ltd [ROIV]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ROIV shares is $16.94 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ROIV stock is a recommendation set at 1.18. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wolfe Research have made an estimate for Roivant Sciences Ltd shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on February 15, 2024. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Overweight. The new note on the price target was released on January 05, 2024, representing the official price target for Roivant Sciences Ltd stock. Previously, the target price had yet another raise to $14, while Deutsche Bank analysts kept a Buy rating on ROIV stock.
The Average True Range (ATR) for Roivant Sciences Ltd is set at 0.30, with the Price to Sales ratio for ROIV stock in the period of the last 12 months amounting to 55.50. The Price to Book ratio for the last quarter was 1.62, with the Price to Cash per share for the same quarter was set at 7.69.
ROIV Stock Performance Analysis:
Roivant Sciences Ltd [ROIV] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.32. With this latest performance, ROIV shares dropped by -1.33% in over the last four-week period, additionally plugging by 10.92% over the last 6 months – not to mention a rise of 17.86% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ROIV stock in for the last two-week period is set at 56.31, with the RSI for the last a single of trading hit 60.82, and the three-weeks RSI is set at 54.78 for Roivant Sciences Ltd [ROIV]. The present Moving Average for the last 50 days of trading for this stock 11.66, while it was recorded at 11.80 for the last single week of trading, and 11.07 for the last 200 days.
Insight into Roivant Sciences Ltd Fundamentals:
Roivant Sciences Ltd’s liquidity data is similarly interesting compelling, with a Quick Ratio of 27.75 and a Current Ratio set at 27.91.
ROIV Stock EPS
With the latest financial reports released by the company, Roivant Sciences Ltd posted -0.4/share EPS, while the average EPS was predicted by analysts to be reported at -0.31/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.09. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ROIV.
Roivant Sciences Ltd [ROIV] Institutonal Ownership Details
There are presently around $74.83%, or 105.53%% of ROIV stock, in the hands of institutional investors. The top three institutional holders of ROIV stocks are: SB INVESTMENT ADVISERS (UK) LTD with ownership of 71.36 million shares, which is approximately 8.8884%. VIKING GLOBAL INVESTORS LP, holding 69.16 million shares of the stock with an approximate value of $$730.98 million in ROIV stocks shares; and VIKING GLOBAL INVESTORS LP, currently with $$705.23 million in ROIV stock with ownership which is approximately 8.3103%.
